DASH diet interventions may positively impact heart failure patients, but definitive evidence is currently limited by small sample sizes and non-randomized study designs.
Does the DASH diet improve outcomes in patients with heart failure?
The DASH diet shows potential for heart failure management, but randomized controlled trials are needed to provide definitive evidence for clinical guidelines.
Heart failure (HF) is a major health care burden increasing in prevalence over time. Effective, evidence-based interventions for HF prevention and management are needed to improve patient longevity, symptom control, and quality of life. Dietary Approaches to Stop Hypertension (DASH) diet interventions can have a positive impact for HF patients. However, the absence of a consensus for comprehensive dietary guidelines and for pragmatic evidence limits the ability of health care providers to implement clinical recommendations. The refinement of medical nutrition therapy through precision nutrition approaches has the potential to reduce the burden of HF, improve clinical care, and meet the needs of diverse patients. The aim of this review is to summarize current evidence related to HF dietary recommendations including DASH diet nutritional interventions and to develop initial recommendations for DASH diet implementation in outpatient HF management. Articles involving human studies were obtained using the following search terms: Dietary Approaches to Stop Hypertension (DASH diet), diet pattern, diet, metabolism, and heart failure. Only full-text articles written in English were included in this review. As DASH nutritional interventions have been proposed, limitations of these studies are the small sample size and non-randomization of interventions, leading to less reliable evidence. Randomized controlled interventions are needed to offer definitive evidence related to the use of the DASH diet in HF management.
Wickman et al. (Fri,) conducted a review in Heart failure. DASH diet was evaluated. DASH diet interventions may positively impact heart failure patients, but definitive evidence is currently limited by small sample sizes and non-randomized study designs.